Trial Profile
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL) Post Marketing Surveillance Protocol.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 19 May 2011 New trial record